The reporting odds ratio and its advantages over the pr

Pharmacoepidemiology and Drug Safety
13, 519-523
DOI: 10.1002/pds.1001

Citation Report

#	Article	IF	Citations
1	Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions. JAMA - Journal of the American Medical Association, 2004, 292, 2643.	3.8	52
2	The reporting odds ratio versus the proportional reporting ratio:â€˜deuceâ€™. Pharmacoepidemiology and Drug Safety, 2004, 13, 525-526.	0.9	61
3	Measuring drug effects means getting a clearer signal. Pharmacoepidemiology and Drug Safety, 2004, 13, 527-528.	0.9	7
5	Disproportionality analyses of spontaneous reports. Pharmacoepidemiology and Drug Safety, 2004, 13, 503-504.	0.9	23
6	The Risk of Anaphylactic Reactions to Rocuronium in the United States Is Comparable to That of Vecuronium: An Analysis of Food and Drug Administration Reporting of Adverse Events. Anesthesia and Analgesia, 2005, 101, 819-822.	1.1	49
7	Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. IEEE Transactions on Information Technology in Biomedicine, 2005, 9, 518-527.	3.6	73
8	The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. Pharmacoepidemiology and Drug Safety, 2005, 14, 285-286.	0.9	47
9	Evaluation of Suspected Adverse Drug Reactionsâ€"Reply. JAMA - Journal of the American Medical Association, 2005, 293, 1324.	3.8	6
10	Perspectives on the Use of Data Mining in Pharmacovigilance. Drug Safety, 2005, 28, 981-1007.	1.4	204
11	Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of spontaneous reports. Clinical Therapeutics, 2006, 28, 1123-1132.	1.1	32
12	Evidence-based Guidelines for the Utilization of Immunostains in Diagnostic Pathology: Pulmonary Adenocarcinoma Versus Mesothelioma. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 140-144.	0.6	32
13	Advances in Statistical Methods for the Health Sciences. , 2007, , .		8
14	Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases. Drug Safety, 2007, 30, 891-898.	1.4	190
15	Telithromycin Use and Spontaneous Reports of Hepatotoxicity. Drug Safety, 2007, 30, 697-703.	1.4	29
16	Gynaecomastia Associated with Proton Pump Inhibitors. Drug Safety, 2007, 30, 527-531.	1.4	22
17	Signal detection methodologies to support effective safety management. Expert Opinion on Drug Safety, 2007, 6, 451-464.	1.0	25
18	Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database. Pharmacoepidemiology and Drug Safety, 2007, 16, 1136-1140.	0.9	13
19	Analysis of longitudinal laboratory data in the presence of common selection mechanisms: A view toward greater emphasis on preâ€marketing pharmaceutical safety. Statistics in Medicine, 2008, 27, 2248-2266.	0.8	3

#	Article	IF	Citations
20	A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding. British Journal of Clinical Pharmacology, 2008, 66, 142-145.	1.1	25
21	Allergic reactions to oral drugs: A case/non-case study from an Italian spontaneous reporting database (GIF). Pharmacological Research, 2008, 58, 202-207.	3.1	34
22	Studying the causes of adverse drug reactions: circumvent the warning-interfered bias using the caseâ€"case comparison approach. Journal of Clinical Epidemiology, 2008, 61, 516.	2.4	8
23	Safety Signals Using Proportional Reporting Ratios from Company and Regulatory Authority Databases. Drug Information Journal, 2008, 42, 205-210.	0.5	3
24	Signal Detection of Adverse Drug Reactions. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2009, 14, 27-36.	0.0	48
25	Signal Detection of Drug Complications Applying Association Rule Learning for Stevens-Johnson Syndrome. Journal of Computer Aided Chemistry, 2009, 10, 118-127.	0.3	5
26	Genotypeâ€"phenotype correlates in Taiwanese patients with earlyâ€onset recessive parkinsonism. Movement Disorders, 2009, 24, 104-108.	2.2	24
27	Prevalence of unilateral tremor in autosomal dominant essential tremor. Movement Disorders, 2009, 24, 108-111.	2.2	35
28	Serotonin and dopamine transporter genes do not influence depression in Parkinson's disease. Movement Disorders, 2009, 24, 111-115.	2.2	21
29	Ultrasound treatment of cutaneous sideâ€effects of infused apomorphine: A randomized controlled pilot study. Movement Disorders, 2009, 24, 115-118.	2.2	26
30	Essential tremor might be less frequent than Parkinson's disease in North Israel Arab villages. Movement Disorders, 2009, 24, 119-122.	2.2	25
31	Increased oxidative stress in patients with amyotrophic lateral sclerosis/Parkinsonismâ€dementia complex in the Kii peninsula, Japan. Movement Disorders, 2009, 24, 123-126.	2.2	10
32	Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine. Movement Disorders, 2009, 24, 126-129.	2.2	78
33	Cardiac and noncardiac fibrotic reactions caused by ergotâ€and nonergotâ€derived dopamine agonists. Movement Disorders, 2009, 24, 129-133.	2.2	65
34	Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome. Movement Disorders, 2009, 24, 133-137.	2.2	18
35	Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiology and Drug Safety, 2009, 18, 427-436.	0.9	551
36	Statins and amyotrophic lateral sclerosis â€" the level of evidence for an association. Journal of Internal Medicine, 2009, 266, 520-526.	2.7	16
37	Heart Rhythm Disturbances Associated With Rupatadine: A Case Series From the Spanish and Portuguese Pharmacovigilance Systems. Clinical Pharmacology and Therapeutics, 2009, 85, 481-484.	2.3	11

#	Article	IF	Citations
38	Effect of Date of Drug Marketing on Disproportionality Measures in Pharmacovigilance. Drug Safety, 2009, 32, 441-447.	1.4	25
39	Priapism Associated With Antipsychotics. Journal of Clinical Psychopharmacology, 2010, 30, 68-71.	0.7	56
40	A novel method for signal detection of adverse drug reactions based on proportional reporting ratios. International Journal of Clinical Pharmacy, 2010, 32, 658-662.	1.4	2
41	Signal detection of rosuvastatin compared to other statins: dataâ€mining study using national health insurance claims database. Pharmacoepidemiology and Drug Safety, 2010, 19, 238-246.	0.9	36
42	Selected control events and reporting odds ratio in signal detection methodology. Pharmacoepidemiology and Drug Safety, 2010, 19, 1159-1165.	0.9	42
43	A potential competition bias in the detection of safety signals from spontaneous reporting databases. Pharmacoepidemiology and Drug Safety, 2010, 19, 1166-1171.	0.9	47
44	Drugâ€induced hepatic injury in children: a case/nonâ€case study of suspected adverse drug reactions in VigiBase. British Journal of Clinical Pharmacology, 2010, 70, 721-728.	1.1	56
45	Sharp bounds on causal effects in case-control and cohort studies. Biometrika, 2010, 97, 123-132.	1.3	9
46	Drug-Induced Taste and Smell Alterations. Drug Safety, 2011, 34, 849-859.	1.4	58
47	Disease-specific adverse events following nonlive vaccines: A paradoxical placebo effect or a nocebo phenomenon?. Vaccine, 2011, 29, 6321-6326.	1.7	15
48	Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. British Journal of Clinical Pharmacology, 2011, 72, 905-908.	1.1	309
49	Potential for Linezolid-Related Blindness: A Review of Spontaneous Adverse Event Reports. Pharmacotherapy, 2011, 31, 585-590.	1.2	7
50	A Likelihood Ratio Test Based Method for Signal Detection With Application to FDAâ€™s Drug Safety Data. Journal of the American Statistical Association, 2011, 106, 1230-1241.	1.8	82
51	Work-related asthma in France: recent trends for the period 2001â€“2009. Occupational and Environmental Medicine, 2012, 69, 391-397.	1.3	76
52	Automatic Drug Adverse Reaction Discovery from Parenting Websites Using Disproportionality Methods. , 2012, , .		15
53	Using Electronic Health Care Records for Drug Safety Signal Detection. Medical Care, 2012, 50, 890-897.	1.1	79
54	Extracting drug adverse and beneficial reactions in pediatric population from healthcare social network. , 2012, , .		0
55	Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). , 0, , .		98

#	Article	IF	Citations
56	Identifying Adverse Events of Vaccines Using a Bayesian Method of Medically Guided Information Sharing. Drug Safety, 2012, 35, 61-78.	1.4	11
57	The role of the KIDS for enhancing drug safety and risk management in Korea. Journal of the Korean Medical Association, 2012, 55, 861.	0.1	7
58	Spontaneously Reported Hepatic Adverse Drug Events in Korea: Multicenter Study. Journal of Korean Medical Science, 2012, 27, 268.	1.1	28
59	Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multiâ€item Gamma Poisson Shrinker. Pharmacoepidemiology and Drug Safety, 2012, 21, 622-630.	0.9	14
60	A shrinkage-based comparative assessment of observed-to-expected disproportionality measures. Pharmacoepidemiology and Drug Safety, 2012, 21, 589-596.	0.9	7
61	Reports of Sexual Disorders Related to Serotonin Reuptake Inhibitors in the French Pharmacovigilance Database: An Example of Underreporting. Drug Safety, 2013, 36, 515-519.	1.4	8
62	Postmarketing Safety Surveillance. Drug Safety, 2013, 36, 183-197.	1.4	91
63	Mining Adverse Drug Reactions from Electronic Health Records. , 2013, , .		3
64	Tigecyclineâ€Related Pancreatitis: A Review of Spontaneous Adverse Event Reports. Pharmacotherapy, 2013, 33, 63-68.	1.2	23
65	Drug safety data mining with a treeâ€based scan statistic. Pharmacoepidemiology and Drug Safety, 2013, 22, 517-523.	0.9	72
66	The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist. European Journal of Clinical Pharmacology, 2013, 69, 33-41.	0.8	14
67	Likelihood Ratio Test-Based Method for Signal Detection in Drug Classes Using FDA's AERS Database. Journal of Biopharmaceutical Statistics, 2013, 23, 178-200.	0.4	34
68	Disproportionality methods for pharmacovigilance in longitudinal observational databases. Statistical Methods in Medical Research, 2013, 22, 39-56.	0.7	96
69	Systems Approaches in Risk Assessment. Clinical Pharmacology and Therapeutics, 2013, 93, 413-424.	2.3	20
70	Association between Acute Myelogenous Leukemia and Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia. Internal Medicine, 2013, 52, 2193-2201.	0.3	18
71	Data Mining of the Public Version of the FDA Adverse Event Reporting System. International Journal of Medical Sciences, 2013, 10, 796-803.	1.1	397
72	Commonality of Drug-associated Adverse Events Detected by 4 Commonly Used Data Mining Algorithms. International Journal of Medical Sciences, 2014, 11, 461-465.	1.1	13
74	Analyzing GeoSentinel Surveillance Data: A Comparison of Methods to Explore Acute Gastrointestinal Illness Among International Travelers. Clinical Infectious Diseases, 2014, 58, 546-554.	2.9	10

#	Article	IF	Citations
76	Linked vaccine adverse event data from VAERS for biomedical data analysis and longitudinal studies. BioData Mining, 2014, 7, 36.	2.2	3
78	Guillainâ€"Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. Human Vaccines and Immunotherapeutics, 2014, 10, 232-237.	1.4	26
79	Likelihood ratio based tests for longitudinal drug safety data. Statistics in Medicine, 2014, 33, 2408-2424.	0.8	18
80	A Review of Statistical Methods for Safety Surveillance. Therapeutic Innovation and Regulatory Science, 2014, 48, 98-108.	0.8	44
81	Hepatotoxicity Related to Agomelatine and Other New Antidepressants. Journal of Clinical Psychopharmacology, 2014, 34, 327-330.	0.7	29
82	Association between an excess risk of acute kidney injury and concomitant use of ibuprofen and acetaminophen in children, retrospective analysis of a spontaneous reporting system. European Journal of Clinical Pharmacology, 2014, 70, 479-482.	0.8	26
84	Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 307-313.	0.7	20
85	Occupational allergic contact dermatitis and major allergens in France: temporal trends for the period 2001-2010. British Journal of Dermatology, 2014, 171, 1375-1385.	1.4	43
87	Acute kidney injury during concomitant use of valacyclovir and loxoprofen: detecting drug-drug interactions in a spontaneous reporting system. Pharmacoepidemiology and Drug Safety, 2014, 23, 1154-1159.	0.9	26
88	Identification of sex-associated network patterns in Vaccine-Adverse Event Association Network in VAERS. Journal of Biomedical Semantics, 2015, 6, 33.	0.9	5
89	Association rule mining in the <scp>US Vaccine Adverse Event Reporting System (VAERS</scp>). Pharmacoepidemiology and Drug Safety, 2015, 24, 922-933.	0.9	9
90	Occupational contact urticaria: lessons from the French National Network for Occupational Disease Vigilance and Prevention (RNV3P). British Journal of Dermatology, 2015, 173, 1453-1461.	1.4	40
91	Signal detection in FDA AERS database using Dirichlet process. Statistics in Medicine, 2015, 34, 2725-2742.	0.8	13
92	Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Design, Development and Therapy, 2015, 9, 3031.	2.0	54
93	Analysis of Adverse Events Associated with the Anti-Allergic Agents Rx-to-OTC-Switched Using Data Mining of the Japanese Adverse Drug Event Report (JADER) Database. Iryo Yakugaku (Japanese Journal of) Tj ETQq0 0 0 rgBT /Overlock 1	0.0	2
94	Detection of signals of abuse and dependence applying disproportionality analysis. European Journal of Clinical Pharmacology, 2015, 71, 229-236.	0.8	18
95	Liver injury with novel oral anticoagulants: assessing postâ€marketing reports in the US Food and Drug Administration adverse event reporting system. British Journal of Clinical Pharmacology, 2015, 80, 285-293.	1.1	66
96	Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase. European Neuropsychopharmacology, 2015, 25, 1556-1565.	0.3	51

#	Article	IF	Citations
97	Twenty years of SHIELD: decreasing incidence of occupational asthma in the West Midlands, UK?. Occupational and Environmental Medicine, 2015, 72, 304-310.	1.3	27
98	Detecting drugâ€"herbal interaction using a spontaneous reporting system database: an example with benzylpenicillin and qingkailing injection. European Journal of Clinical Pharmacology, 2015, 71, 1139-1145.	0.8	19
99	Methods and Issues to Consider for Detection of Safety Signals From Spontaneous Reporting Databases: A Report of the DIA Bayesian Safety Signal Detection Working Group. Therapeutic Innovation and Regulatory Science, 2015, 49, 65-75.	0.8	7
100	Evaluation of statistical methods for safety signal detection: a simulation study. Pharmaceutical Statistics, 2015, 14, 11-19.	0.7	6
101	Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. Fundamental and Clinical Pharmacology, 2016, 30, 162-171.	1.0	14
102	Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database. Clinical Drug Investigation, 2016, 36, 735-742.	1.1	35
103	Adverse drug reactions of systemic antihistamines in children in the Netherlands. Archives of Disease in Childhood, 2016, 101, 968-970.	1.0	17
104	Statistical Monitoring of Safety in Clinical Trials. Statistics in Biopharmaceutical Research, 2016, 8, 88-105.	0.6	11
105	Outcome of antiepileptic drug treatment of 1282 patients with epilepsy, their pharmacovigilance reports and concomitant medication on CNS in an East-Hungarian adult database. Journal of the Neurological Sciences, 2016, 369, 220-226.	0.3	9
106	Adverse Reaction Prediction and Pharmacovigilance of Nutraceuticals. , 2016, , 239-248.		1
107	An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies. Drug Safety, 2016, 39, 29-43.	1.4	35
108	Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from VigibaseÂ®. Drug Safety, 2016, 39, 689-696.	1.4	29
109	What Is the Plural of a â€˜Yellowâ€™ Anecdote?. Drug Safety, 2016, 39, 1-3.	1.4	6
110	Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. Pharmacological Research, 2016, 104, 108-114.	3.1	52
111	Dipeptidyl Peptidase-4 Inhibitorâ€"Associated Pancreatic Carcinoma. Annals of Pharmacotherapy, 2016, 50, 27-31.	0.9	23
112	Evaluating the impact of design pattern and anti-pattern dependencies on changes and faults. Empirical Software Engineering, 2016, 21, 896-931.	3.0	36
113	Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS). Journal of Oncology Pharmacy Practice, 2017, 23, 93-102.	0.5	23
114	Zero-inflated Poisson model based likelihood ratio test for drug safety signal detection. Statistical Methods in Medical Research, 2017, 26, 471-488.	0.7	20

#	Article	IF	Citations
116	Effect of statins on blood pressure: Analysis on adverse events released by FDA. Clinical and Experimental Hypertension, 2017, 39, 325-329.	0.5	12
117	Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database. Psychiatry Research, 2017, 256, 237-242.	1.7	23
118	Logistic Regression Likelihood Ratio Test Analysis for Detecting Signals of Adverse Events in Post-market Safety Surveillance. Journal of Biopharmaceutical Statistics, 2017, 27, 990-1008.	0.4	13
119	Safety of ceftriaxone in paediatrics: a systematic review protocol. BMJ Open, 2017, 7, e016273.	0.8	6
120	Adverse drug reactions of montelukast in children and adults. Pharmacology Research and Perspectives, 2017, 5, e00341.	1.1	56
121	Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System. Scientific Reports, 2017, 7, 5527.	1.6	34
122	MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia. EBioMedicine, 2017, 26, 132-137.	2.7	7
123	Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1108-1113.	1.1	83
124	An original pharmacoepidemiologicalâ€"pharmacodynamic method: application to antipsychoticâ€induced movement disorders. British Journal of Clinical Pharmacology, 2017, 83, 612-622.	1.1	29
125	Differences in VigiBaseÂ® reporting of aminoglycoside and capreomycinâ€suspected ototoxicity during tuberculosis treatment. Pharmacoepidemiology and Drug Safety, 2017, 26, 1-8.	0.9	18
126	Clindamycin hydrochloride and clindamycin phosphate: two drugs or one? A retrospective analysis of a spontaneous reporting system. European Journal of Clinical Pharmacology, 2017, 73, 251-253.	0.8	3
127	Blood Pressure Elevation Associated with Topical Prostaglandin F2Î± Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases. Biological and Pharmaceutical Bulletin, 2017, 40, 616-620.	0.6	7
128	Carboplatin-induced hematotoxicity among patients with non-small cell lung cancer: Analysis on clinical adverse events and drug-gene interactions. Oncotarget, 2017, 8, 32228-32236.	0.8	20
129	Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer. Oncotarget, 2017, 8, 18417-18423.	0.8	13
130	Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database. PLoS ONE, 2017, 12, e0182045.	1.1	10
131	A signal detection method for temporal variation of adverse effect with vaccine adverse event reporting system data. BMC Medical Informatics and Decision Making, 2017, 17, 76.	1.5	12
132	Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database. Yakugaku Zasshi, 2017, 137, 111-120.	0.0	22
133	Demographic and socioeconomic characteristics of outpatients could modify their attitude towards misusing medications in northern Jordan. Journal of Public Health Research, 2017, 6, 818.	0.5	5

#	Article	IF	Citations
134	Digoxin-induced anemia among patients with atrial fibrillation and heart failure: clinical data analysis and drug-gene interaction network. Oncotarget, 2017, 8, 57003-57011.	0.8	11
135	Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement. International Journal of Molecular Sciences, 2017, 18, 101.	1.8	3
136	Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance. Therapeutic Innovation and Regulatory Science, 2018, 52, 159-169.	0.8	18
137	Adverse drug event profile associated with pregabalin among patients with and without cancer: analysis of a spontaneous reporting database. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 543-549.	0.7	11
138	Extended likelihood ratio test-based methods for signal detection in a drug class with application to FDAâ€™s adverse event reporting system database. Statistical Methods in Medical Research, 2018, 27, 876-890.	0.7	16
139	Important statistical considerations in the evaluation of postâ€market studies to assess whether opioids with abuseâ€deterrent properties result in reduced abuse in the community. Pharmacoepidemiology and Drug Safety, 2018, 27, 473-478.	0.9	8
140	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncology, The, 2018, 19, 1579-1589.	5.1	742
141	Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA. Pharmacoepidemiology and Drug Safety, 2018, 27, 1402-1408.	0.9	34
142	Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study. BioDrugs, 2018, 32, 607-617.	2.2	11
143	Risk of Hypoglycemia After Concomitant Use of Antidiabetic, Antihypertensive, and Antihyperlipidemic Medications: A Database Study. Journal of Clinical Pharmacology, 2018, 58, 1324-1331.	1.0	9
145	Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database. Clinical Drug Investigation, 2018, 38, 867-872.	1.1	7
146	Mining Patients' Narratives in Social Media for Pharmacovigilance: Adverse Effects and Misuse of Methylphenidate. Frontiers in Pharmacology, 2018, 9, 541.	1.6	39
147	Pillars and Pitfalls of the New Pharmacovigilance Legislation: Consequences for the Identification of Adverse Drug Reactions Deriving From Abuse, Misuse, Overdose, Occupational Exposure, and Medication Errors. Frontiers in Pharmacology, 2018, 9, 611.	1.6	16
148	Adverse reaction signal detection methodology in pharmacoepidemiology. European Journal of Epidemiology, 2018, 33, 507-508.	2.5	3
149	Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database. Diabetes Care, 2018, 41, e130-e132.	4.3	61
150	Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. Heart, 2018, 104, 1859-1863.	1.2	37
151	Signal detection for bleeding associated with the use of direct oral anticoagulants. American Journal of Health-System Pharmacy, 2018, 75, 973-977.	0.5	4
152	Analyses of non-benzodiazepine-induced adverse events and prognosis in elderly patients based on the Japanese adverse drug event report database. Journal of Pharmaceutical Health Care and Sciences, 2018, 4, 10.	0.4	8

#	Article	IF	Citations
153	Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. Journal of Cardiac Failure, 2018, 24, 533-536.	0.7	14
154	Detecting Pharmacovigilance Signals Combining Electronic Medical Records With Spontaneous Reports: A Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis. Frontiers in Pharmacology, 2018, 9, 875.	1.6	23
155	Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administrationâ€™s Adverse Event Reporting System. Drug Safety, 2019, 42, 85-93.	1.4	5
156	Relationship of clinical adverse event reports to models of arrhythmia risk. Journal of Pharmacological and Toxicological Methods, 2019, 100, 106622.	0.3	2
157	Adverse Drug Reaction Risk Measures: A Comparison of Estimates from Drug Surveillance and Randomised Trials. Pharmaceutical Medicine, 2019, 33, 331-339.	1.0	7
158	Safety of azithromycin in paediatrics: a systematic review protocol. BMJ Paediatrics Open, 2019, 3, e000469.	0.6	4
159	Early signal detection of adverse events following influenza vaccination using proportional reporting ratio, Victoria, Australia. PLoS ONE, 2019, 14, e0224702.	1.1	13
160	Cataracts and statins. A disproportionality analysis using data from VigiBase. Regulatory Toxicology and Pharmacology, 2019, 109, 104509.	1.3	4
161	Comparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database. Therapeutic Advances in Drug Safety, 2019, 10, 204209861987673.	1.0	4
162	Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. Journal of Neuro-Oncology, 2019, 145, 1-9.	1.4	69
163	Cardiovascular Toxicities AssociatedÂWith Ibrutinib. Journal of the American College of Cardiology, 2019, 74, 1667-1678.	1.2	169
164	Safety profile of traditional Chinese herbal injection: An analysis of a spontaneous reporting system in China. Pharmacoepidemiology and Drug Safety, 2019, 28, 1002-1013.	0.9	38
165	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. , 2019, 7, 134.		237
166	Is <scp>TNF</scp> inhibitor exposure a risk factor for amyotrophic lateral sclerosis?. Fundamental and Clinical Pharmacology, 2019, 33, 689-694.	1.0	5
167	Likelihood-Ratio-Test Methods for Drug Safety Signal Detection from Multiple Clinical Datasets. Computational and Mathematical Methods in Medicine, 2019, 2019, 1-11.	0.7	5
168	Analysis of the Association of Administration of various glucocorticoids with development of acute pancreatitis using US Food and Drug Administration adverse event reporting system (FAERS). Journal of Pharmaceutical Health Care and Sciences, 2019, 5, 5.	0.4	9
169	Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of evelolimus use with diabetes. Endocrine Journal, 2019, 66, 571-574.	0.7	10
170	Efficient Methods for Signal Detection From Correlated Adverse Events in Clinical Trials. Biometrics, 2019, 75, 1000-1008.	0.8	3

#	Article	IF	Citations
171	A Comparison Study of Algorithms to Detect Drugâ€"Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches. Drug Safety, 2019, 42, 743-750.	1.4	35
173	Osimertinib-Induced Cardiotoxicity. JACC: CardioOncology, 2019, 1, 172-178.	1.7	66
174	Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports. BMC Medical Informatics and Decision Making, 2019, 19, 279.	1.5	13
175	Rhabdomyolysis risk from the use of twoâ€drug combination of antidyslipidemic drugs with antihypertensive and antidiabetic medications: a signal detection analysis. Fundamental and Clinical Pharmacology, 2019, 33, 339-346.	1.0	4
176	Cutaneous adverse drug reactions to psychotropic drugs and their risk factors â€" a case-control study. European Neuropsychopharmacology, 2019, 29, 111-121.	0.3	15
177	Reply to Hardalo et al., â€œMyelosuppression with Oxazolidinones: Are There Differences?â€. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	0
178	Pharmacoepidemiology in the Prevention of Adverse Drug Reactions. , 2019, , 25-65.		6
179	Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. Archives of Cardiovascular Diseases, 2020, 113, 9-21.	0.7	27
180	Complementing Observational Signals with Literature-Derived Distributed Representations for Post-Marketing Drug Surveillance. Drug Safety, 2020, 43, 67-77.	1.4	7
181	Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization. Clinical Genitourinary Cancer, 2020, 18, 192-200.e2.	0.9	9
182	Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism and Related Disorders, 2020, 70, 55-59.	1.1	14
183	Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study. Drug Safety, 2020, 43, 1315-1322.	1.4	33
184	A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opinion on Drug Safety, 2020, 19, 1505-1511.	1.0	39
185	Uses of pharmacovigilance databases: An overview. Therapie, 2020, 75, 591-598.	0.6	92
186	Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events. Gastroenterology, 2020, 159, 1195-1200.e1.	0.6	5
187	Likelihood Ratio Test Method for Multiple Medical Devices Comparison Using Multiple-Site Data with Continuous Outcomes. Therapeutic Innovation and Regulatory Science, 2020, 54, 1444-1452.	0.8	0
188	Differences in risk factors for anticoagulantâ€related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database. British Journal of Clinical Pharmacology, 2021, 87, 2977-2981.	1.1	4
189	Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. Ocular Immunology and Inflammation, 2022, 30, 191-197.	1.0	26

#	Article	IF	Citations
190	Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation, 2020, 142, 2443-2455.	1.6	121
191	Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. Pharmaceuticals, 2020, 13, 325.	1.7	23
192	Exploring pharmacogenetic difference using adverse event database: an example of clopidogrel and cardiovascular events. Pharmacogenomics, 2020, 21, 1157-1168.	0.6	2
193	Predicting Drug Risk Level from Adverse Drug Reactions Using SMOTE and Machine Learning Approaches. IEEE Access, 2020, 8, 185761-185775.	2.6	17
194	Extended multiâ€item gamma Poisson shrinker methods based on the <scp>zeroâ€inflated Poisson</scp> model for postmarket drug safety surveillance. Statistics in Medicine, 2020, 39, 4636-4650.	0.8	4
195	Safety concerns reported by consumers, manufacturers and healthcare professionals: A detailed evaluation of opioidâ€related adverse drug reactions in the <scp>FDA</scp> database over 15â€‰years. Pharmacoepidemiology and Drug Safety, 2020, 29, 1627-1635.	0.9	9
196	Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance. Life, 2020, 10, 138.	1.1	16
197	Deep Learning for Adverse Event Detection from Web Search. IEEE Transactions on Knowledge and Data Engineering, 2020, , 1-1.	4.0	12
198	Subset Analysis for Screening Drugâ€"Drug Interaction Signal Using Pharmacovigilance Database. Pharmaceutics, 2020, 12, 762.	2.0	10
199	Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open, 2020, 5, e000866.	2.0	34
200	Minimization of masking in signal detection from Chinese spontaneous reporting databases based on data removal strategy. , 2020, , .		0
201	T-cell lymphoma secondary to checkpoint inhibitor therapy. , 2020, 8, e000104.		25
202	Antineoplastic Drug-induced Aortitis: An Unraveled Adverse Effect Using the World Health Organization Pharmacovigilance Database. Journal of Rheumatology, 2020, 47, 1298-1300.	1.0	4
203	A Bayesian hierarchical approach for multiple outcomes in routinely collected healthcare data. Statistics in Medicine, 2020, 39, 2639-2654.	0.8	2
204	Association between oral anticoagulants and osteoporosis: Real-world data mining using a multi-methodological approach. International Journal of Medical Sciences, 2020, 17, 471-479.	1.1	19
205	Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation. Cancers, 2020, 12, 1650.	1.7	21
206	Dolutegravir and neural tube defects: a new insight. Lancet Infectious Diseases, The, 2020, 20, 405-406.	4.6	14
207	Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database. Clinical Drug Investigation, 2020, 40, 873-881.	1.1	3

#	Article	IF	Citations
208	Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. European Child and Adolescent Psychiatry, 2021, 30, 1047-1058.	2.8	3
209	Borrowing external information to improve Bayesian confidence propagation neural network. European Journal of Clinical Pharmacology, 2020, 76, 1311-1319.	0.8	6
210	Detecting potential signals of adverse drug events from prescription data. Artificial Intelligence in Medicine, 2020, 104, 101839.	3.8	11
211	Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data. Toxicology and Applied Pharmacology, 2020, 395, 114976.	1.3	10
212	Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. BioScience Trends, 2020, 14, 139-143.	1.1	35
213	Bacillus Calmetteâ€"GuÃ©rin (BCG) vaccine safety surveillance in the Korea Adverse Event Reporting System using the tree-based scan statistic and conventional disproportionality-based algorithms. Vaccine, 2020, 38, 3702-3710.	1.7	10
214	Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. JAMA Dermatology, 2021, 157, 35.	2.0	57
215	Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System. Drug Safety, 2021, 44, 107-119.	1.4	16
216	Risk of haematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: Analysis of the Japanese Adverse Drug Event Report database. British Journal of Clinical Pharmacology, 2021, 87, 2286-2289.	1.1	4
217	Renal ischemic adverse drug events related to tranexamic acid in women of child-bearing age: an analysis of pharmacovigilance data. European Journal of Clinical Pharmacology, 2021, 77, 913-919.	0.8	4
218	SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database. Journal of Clinical Pharmacology, 2021, 61, 187-192.	1.0	22
219	Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. Psychotherapy and Psychosomatics, 2021, 90, 41-48.	4.0	63
220	Differences in detected safety signals between benzodiazepines and non-benzodiazepine hypnotics: pharmacovigilance study using a spontaneous reporting system. International Journal of Medical Sciences, 2021, 18, 1130-1136.	1.1	7
221	Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 341-348.	1.0	17
222	Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. BioDrugs, 2021, 35, 239-254.	2.2	6
223	Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. Lung, 2021, 199, 199-211.	1.4	7
224	Betaâ€blockerâ€associated hypoglycaemia: New insights from a realâ€world pharmacovigilance study. British Journal of Clinical Pharmacology, 2021, 87, 3320-3331.	1.1	8
225	A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Cardiovascular Drugs and Therapy, 2022, 36, 309-322.	1.3	12

#	Article	IF	Citations
226	Hyponatremia Following Antipsychotic Treatment: In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review. International Journal of Neuropsychopharmacology, 2021, 24, 477-489.	1.0	8
227	Overview of HIV treatment failure in Africa using the WHO Pharmacovigilance data. Tropical Medicine and International Health, 2021, 26, 530-534.	1.0	0
228	Worsening of myasthenia due to antiepileptic, antipsychotic, antidepressant, and sedative medication: An estimation of risk based on reporting frequency. European Journal of Neurology, 2021, 28, 2349-2356.	1.7	3
229	Change Point Analysis for Detecting Vaccine Safety Signals. Vaccines, 2021, 9, 206.	2.1	10
230	Monitoring vaccine safety by studying temporal variation of adverse events using vaccine adverse event reporting system. Annals of Applied Statistics, 2021, 15, .	0.5	3
231	Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer. Pharmaceuticals, 2021, 14, 377.	1.7	7
232	Effect of antipsychotics on breast tumors by analysis of the Japanese Adverse Drug Event Report database and cell-based experiments. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 13.	0.4	2
233	Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan. Schizophrenia Research, 2021, 231, 42-46.	1.1	8
234	Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. European Journal of Clinical Pharmacology, 2021, 77, 1513-1521.	0.8	3
235	Nephrotoxicity of immune checkpoint inhibitor therapy: a pharmacovigilance study. Nephrology Dialysis Transplantation, 2021, , .	0.4	1
236	Visual-vestibular mismatch correlates with headache. Journal of Vestibular Research: Equilibrium and Orientation, 2021, 31, 173-180.	0.8	7
237	Ocular Safety Profile of BRAF and MEK Inhibitors. Ophthalmology, 2021, 128, 1748-1755.	2.5	17
238	Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database. International Journal of Clinical Pharmacy, 2021, 43, 1508-1515.	1.0	3
240	Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity. Scientific Reports, 2021, 11, 13349.	1.6	4
241	Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database. Clinical Drug Investigation, 2021, 41, 615-627.	1.1	3
242	Data mining for detecting signals of adverse drug reaction of doxycycline using the Korea adverse event reporting system database. Journal of Dermatological Treatment, 2022, 33, 2192-2197.	1.1	4
243	Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. Journal of Clinical Epidemiology, 2021, 134, 14-21.	2.4	42
244	Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection. Drugs - Real World Outcomes, 2021, 8, 547-554.	0.7	3

#	Article	IF	Citations
245	Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects. Frontiers in Pharmacology, 2021, 12, 655605.	1.6	11
246	Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data. International Journal of Clinical Pharmacy, 2021, 43, 1116-1122.	1.0	10
247	The Impact of Serotonin Transporter Binding Affinity on the Risk of Bleeding Related to Antidepressants. Journal of Clinical Psychopharmacology, 2021, 41, 470-473.	0.7	2
248	The risk of worsening of myasthenia by cardiovascular medication as reflected by reporting frequency. European Journal of Neurology, 2021, 28, 2965-2970.	1.7	3
249	Relative Risk Analysis of Liver-related Adverse Drug Reactions in Children Based on Chinaâ€™s National Spontaneous Reporting System. Journal of Pediatrics, 2021, 234, 85-91.	0.9	6
250	Augmenting aer2vec: Enriching distributed representations of adverse event report data with orthographic and lexical information. Journal of Biomedical Informatics, 2021, 119, 103833.	2.5	3
251	Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase. Scientific Reports, 2021, 11, 14293.	1.6	9
252	Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. Gynecologic Oncology, 2021, 162, 496-505.	0.6	19
253	Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador. Vaccine, 2021, 39, 4849-4855.	1.7	3
254	Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008â€“2017. BMJ Open, 2021, 11, e045948.	0.8	3
255	Patient Drug Database: Construction of Database for Patient Leading Drug Side Effects Exploration Using Patient Generated Health Data. Journal of Health Informatics and Statistics, 2021, 46, 315-325.	0.1	0
256	Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database. Journal of Alzheimer's Disease, 2021, 82, 1333-1344.	1.2	5
257	Risk of neuropsychiatric adverse events associated with varenicline treatment for smoking cessation among Dutch population: A sequence symmetry analysis. Pharmacoepidemiology and Drug Safety, 2022, 31, 158-166.	0.9	4
258	Stress cardiomyopathy (Takotsubo syndrome) in patients who received adrenergic agonist drugs: A pharmacovigilance study using the Japanese Adverse Drug Event Report (JADER) database. Journal of Cardiology, 2021, 79, 36-41.	0.8	5
259	Geriatrics on beers criteria medications at risk of adverse drug events using real-world data. International Journal of Medical Informatics, 2021, 154, 104542.	1.6	3
260	Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBaseÂ®). Bone, 2021, 153, 116137.	1.4	9
261	Analysis of fatal adverse drug events recorded in several Italian emergency departments (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 102	1.0	9
262	Adverse outcomes associated with the treatment of Toxoplasma infections. Scientific Reports, 2021, 11, 1035.	1.6	29

#	Article	IF	Citations
263	Pharmacoepidemiology. , 2014, , 1875-1925.		13
264	Linked Vaccine Adverse Event Data Representation from VAERS for Biomedical Informatics Research. Lecture Notes in Computer Science, 2014, , 652-661.	1.0	2
265	Association of hepatitis B with antirheumatic drugs: a caseâ€"control study. Modern Rheumatology, 2013, 23, 694-704.	0.9	20
269	Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events. Journal of Medical Internet Research, 2016, 18, e76.	2.1	16
270	The Association between Ranitidine Use and Gastrointestinal Cancers. Cancers, 2021, 13, 24.	1.7	18
271	Improved Detection Criteria for Detecting Drug-Drug Interaction Signals Using the Proportional Reporting Ratio. Pharmaceuticals, 2021, 14, 4.	1.7	7
272	Signal Detection of Adverse Drug Reaction of Zolpidem Using the Korea Adverse Event Reporting System Database. The Journal of Health Technology Assessment, 2018, 6, 43-49.	0.2	2
274	New Strategy for Pharmacovigilance Using Data-Mining Methods in Pharmaceuticals and Medical Devices Agency. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2010, 15, 23-30.	0.0	8
275	Detection of Signals of Convulsion-inducing Effect for Fluoroquinolone Antibiotics Alone and with Co-administration of Nonsteroidal Anti-inflammatory Drugs in Association with Aging Using Japanese Adverse Drug Event Reporting Database. Japanese Journal of Clinical Pharmacology and Therapeutics, 2019, 50, 203-209.	0.1	1
276	Signal Detection of Serious Infections Following Treatment with Biologics for Rheumatoid Arthritis:. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2014, 40, 586-594.	0.0	4
277	Analysis of Effects of the Diuretics on Levels of Blood Potassium and Blood Sodium with Angiotensin Receptor Blockers and Thiazide Diuretics Combination Therapy: Data Mining of the Japanese Adverse Drug Event Report Database, JADER. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0 rgBT /Overlock 10	0.0	10
278	Syndromic surveillance in companion animals utilizing electronic medical records data: development and proof of concept. PeerJ, 2016, 4, e1940.	0.9	16
279	Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program. Mental Health Clinician, 2020, 10, 70-75.	0.5	7
280	Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study. Rheumatology, 2022, 61, 865-867.	0.9	37
281	Drug-Induced Respiratory Disease in Cardiac Patients. Medical Radiology, 2009, , 131-157.	0.0	0
282	Flexible Ubiquitous Learning Management System Adapted to Learning Context. Communications in Computer and Information Science, 2010, , 48-59.	0.4	1
283	Data Mining in Pharmacoepidemiological Databases. , 2013, , 351-364.		0
284	Signal Detection of hepatitis B and hepatitis C by molecularly-targeted drugs for cancer:. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2014, 40, 268-277.	0.0	4

#	Article	IF	Citations
285	Quantitative Pharmacovigilance Modeling for TCM Injections Adverse Event Reporting. Journal of Pharmacovigilance, 2014, 02, .	0.2	0
286	Mining for Adverse Drug Events on Twitter. , 2014, , .		1
287	Analysis of Adverse Events Associated with Angiotensin Receptor Blockers and Hydrochlorothiazide Fixed-dose Combination: Data Mining of the Japanese Adverse Drug Event Report Database, JADER. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2015, 41, 347-354.	0.0	3
288	Signal Management of Disproportionate Reporting in Moroccan Pharmacovigilance: The Lower Limb Edema Induced by Anti-Tuberculosis Drugs. Journal of Pharmacovigilance, 2015, 03, .	0.2	0
289	Signal Detection Analysis of Serious Adverse Events Associated with the Digestive Disorder Treatment Agents Rx-To-OTC Switched. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5		1
290	Development and Application of an Alert System to Detect Cases of Food Poisoning in Japan. PLoS ONE, 2016, 11, e0156395.	1.1	4
291	Risk of Drug-Induced Accidents and Injuries in Elderly Patients Treated with Specific Drugs Rather than Polypharmacy : Analyses of the Japanese Adverse Drug Event Report Database. The Showa University Journal of Medical Sciences, 2019, 31, 125-137.	0.1	0
292	Analysis of Adverse Events Associated with Low-dose Estrogen-Progestin Based on Data from the Japanese Adverse Drug Event Report Database and the Relief System for Sufferers from Adverse Drug Reactions. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2019, 45, 115-124.	0.0	0
293	Drug-Associated Delirium Identified in The Food and Drug Administration Adverse Events Reporting System. Psychological Disorders and Research, 2019, , 1-7.	0.1	2
296	Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clinical and Translational Science, 2022, 15, 501-513.	1.5	21
297	Detection and Evaluation of Adverse Drug Reaction Signals of Antidepressants Based on FDA Adverse Event Reporting System Database. Open Journal of Depression, 2020, 09, 17-25.	0.2	2
298	Deep learning from spontaneous reporting systems data to detect ADR signals. , 2020, , .		1
299	Spontaneous Reporting System Modelling for the Evaluation of Automatic Signal Generation Methods in Pharmacovigilance. , 2007, , 75-92.		0
300	1ï¼ŽSpontaneous Report Database and Case-control Studies. Japanese Journal of Pharmacoepidemiology/Yakuzai Ekigaku, 2020, 25, 56-63.	0.0	0
303	Automatic adverse drug events detection using letters to the editor. AMIA ... Annual Symposium proceedings, 2012, 2012, 1030-9.	0.2	6
304	Discovering adverse drug events combining spontaneous reports with electronic medical records: a case study of conventional DMARDs and biologics for rheumatoid arthritis. AMIA Summits on Translational Science Proceedings, 2017, 2017, 95-103.	0.4	9
305	Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (Faers) Database. Journal of Reproduction and Infertility, 2018, 19, 152-156.	1.0	3
306	Detecting Signals of Dietary Supplement Adverse Events from the CFSAN Adverse Event Reporting System (CAERS). AMIA Summits on Translational Science Proceedings, 2019, 2019, 258-266.	0.4	4

#	Article	IF	Citations
307	: Distributed Representations of Adverse Event Reporting System Data as a Means to Identify Drug/Side-Effect Associations. AMIA ... Annual Symposium proceedings, 2019, 2019, 717-726.	0.2	4
308	Retrofitting Vector Representations of Adverse Event Reporting Data to Structured Knowledge to Improve Pharmacovigilance Signal Detection. AMIA ... Annual Symposium proceedings, 2020, 2020, 383-392.	0.2	1
309	Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources. Lancet Regional Health - Europe, The, 2022, 13, 100266.	3.0	39
310	Association Between the Use of Sodiumâ€Glucose Cotransporterâ€2 Inhibitors and Drugâ€Induced Acute Kidney Injury: Analysis of 2 Databases. Journal of Clinical Pharmacology, 2022, 62, 631-635.	1.0	2
311	Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database. Frontiers in Medicine, 2021, 8, 648164.	1.2	8
312	Association Between Pentosan Polysulfate Sodium and Retinal Disorders. JAMA Ophthalmology, 2021, , .	1.4	2
313	TEDAR: Temporal dynamic signal detection of adverse reactions. Artificial Intelligence in Medicine, 2021, 122, 102212.	3.8	2
314	An AdaBoost-Inspired Ensemble Method for ADR Signal Detection. , 2020, , .		2
315	Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System. Cardiovascular Therapeutics, 2022, 2022, 1-9.	1.1	7
316	Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System. Frontiers in Pharmacology, 2021, 12, 772768.	1.6	7
317	Social Media Analytics for Pharmacovigilance of Antiepileptic Drugs. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-24.	0.7	2
318	Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States. Frontiers in Public Health, 2021, 9, 756633.	1.3	36
319	Activeâ€comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors. British Journal of Clinical Pharmacology, 2023, 89, 431-439.	1.1	11
320	Thromboembolism and Oral Contraceptives During the COVID-19 Pandemic: A Disproportionality Analysis Within the Spanish Pharmacovigilance Database. Drugs - Real World Outcomes, 2022, 9, 211-218.	0.7	3
321	Analysis of Water Intoxication by Drugs Using the Japanese Adverse Drug Event Report (JADER) Database. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2021, 47, 91-95.	0.0	0
322	Drugâ€"Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data. Drug Safety, 2022, 45, 287-295.	1.4	7
323	Colistin-associated Stevens-Johnson syndrome and toxic epidermal necrolysis reactions: a retrospective case-non-case pharmacovigilance study. Expert Opinion on Drug Safety, 2022, , 1-6.	1.0	2
324	Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database. Thrombosis Journal, 2022, 20, 12.	0.9	13

#	Article	IF	Citations
325	Challenges and Opportunities of Real-World Data: Statistical Analysis Plan for the Optimise:MS Multicenter Prospective Cohort Pharmacovigilance Study. Frontiers in Neurology, 2022, 13, 799531.	1.1	0
326	Age-Associated Risk of Liver-Related Adverse Drug Reactions. Frontiers in Medicine, 2022, 9, 832557.	1.2	3
327	Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS). Drugs - Real World Outcomes, 2022, , 1.	0.7	16
328	Discovering Drug-Drug Associations in the FDA Adverse Event Reporting System Database with Data Mining Approaches. , 2021, , .		0
329	COVID Vaccine and Cardiovascular Risks: A Natural Language Analysis of Vaccine Adverse Event Reports. , 2021, , .		0
330	Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting database. BioScience Trends, 2022, , .	1.1	1
331	Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitorsâ€‰Â±â€‰androgen deprivation therapy: a pharmacovigilance study. Prostate Cancer and Prostatic Diseases, 2022, , .	2.0	4
332	Cancer risk in individuals with autism spectrum disorder. Annals of Oncology, 2022, 33, 713-719.	0.6	10
345	Increased risk of urinary tract infection and pyelonephritis under concomitant use of sodiumâ€dependent glucose cotransporter 2 inhibitors with antidiabetic, antidyslipidemic, and antihypertensive drugs: An observational study. Fundamental and Clinical Pharmacology, 2022, 36, 1106-1114.	1.0	4
347	Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases. EClinicalMedicine, 2022, 48, 101425.	3.2	4
348	A Disproportionality Analysis for Association of Systemic Capillary Leak Syndrome with COVID-19 Vaccination Using the World Health Organization Pharmacovigilance Database. Vaccines, 2022, 10, 835.	2.1	5
349	Association of Cerebral Venous Thrombosis with mRNA COVID-19 Vaccines: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database. Vaccines, 2022, 10, 799.	2.1	13
350	Risk of systemic vasculitis following mRNA COVID-19 vaccination: a pharmacovigilance study. Rheumatology, 2022, 61, e363-e365.	0.9	5
351	Adverse Drug Reactions of Intranasal Corticosteroids in the Netherlands: An Analysis from the Netherlands Pharmacovigilance Center. Drugs - Real World Outcomes, 0, , .	0.7	6
352	Comparative Safety Signal Assessment of Hospitalization Associated With the Use of Atypical Antipsychotics. Frontiers in Psychiatry, 2022, 13, .	1.3	3
353	Association between Antiâ€Osteoporotic Drugs and Risk of Acute Kidney Injury: A Crossâ€Sectional Study Using Disproportional Analysis and a Pharmacovigilance Database. Journal of Clinical Pharmacology, 0, , .	1.0	0
354	Association of Aggression and Antiepileptic Drugs: Analysis Using the Japanese Adverse Drug Event Report (JADER) Database. Biological and Pharmaceutical Bulletin, 2022, 45, 720-723.	0.6	3
355	Opioid-induced respiratory depression and risk factors in a tertiary hospital: A retrospective study. Saudi Pharmaceutical Journal, 2022, 30, 1095-1100.	1.2	1

#	Article	IF	Citations
356	Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data. Frontiers in Pharmacology, 0, 13, .	1.6	8
357	A pharmacovigilance study of terbinafine indication and liver enzyme elevation. JAAD International, 2022, 8, 114-115.	1.1	2
358	Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system. BMC Infectious Diseases, 2022, 22, .	1.3	2
359	Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database. Frontiers in Pharmacology, 0, 13, .	1.6	0
360	A Disproportionality Analysis of Drugâ€"Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS). Drug Safety, 0, , .	1.4	3
361	Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports. Cardio-Oncology, 2022, 8, .	0.8	2
362	A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database. Multiple Sclerosis Journal, 2022, 28, 2112-2123.	1.4	7
363	Associations of Guillainâ€BarrÃ© syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database. Journal of the Peripheral Nervous System, 2022, 27, 206-214.	1.4	12
364	Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system. EClinicalMedicine, 2022, 50, 101535.	3.2	16
365	Adverse event classification and signal detection of data from the customer service and pharmacovigilance of a multinational veterinary pharmaceutical company. Preventive Veterinary Medicine, 2022, 206, 105704.	0.7	0
366	Decoding kinase-adverse event associations for small molecule kinase inhibitors. Nature Communications, 2022, 13, .	5.8	5
367	Evaluation of Thyroid Dysfunction Associated with the Use of Molecular Targeted Antineoplastic Drugs Using the Japanese Adverse Drug Event Report Database. Iryo Yakugaku (Japanese Journal of) Tj ETQq1 1 0.784314 rgBT /Overlo	0.4	0
368	Short communication: Comments on hair disorders associated with dupilumab based on VigiBase. PLoS ONE, 2022, 17, e0270906.	1.1	1
369	Generalised weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data. Frontiers in Pharmacology, 0, 13, .	1.6	1
370	Temporal Pattern of Cardiac Adverse Events Associated with EGFR-TKIs in Lung Cancer Patients: A Pharmacovigilance Analysis. SSRN Electronic Journal, 0, , .	0.4	0
371	Potential safety signals for antibacterial agents from the Brazilian national pharmacovigilance database (Vigimed/VigiFlow). Frontiers in Pharmacology, 0, 13, .	1.6	0
372	Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system. Frontiers in Immunology, 0, 13, .	2.2	7
373	Detecting early safety signals of infliximab using machine learning algorithms in the Korea adverse event reporting system. Scientific Reports, 2022, 12, .	1.6	2

#	Article	IF	Citations
374	A tree-based scan statistic for zero-inflated count data in post-market drug safety surveillance. Scientific Reports, 2022, 12, .	1.6	1
375	COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS). BMC Women's Health, 2022, 22, .	0.8	17
376	A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab. Expert Opinion on Drug Safety, 2023, 22, 339-342.	1.0	1
377	Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database. Diagnostics, 2022, 12, 2434.	1.3	2
378	Associations of neuralgic amyotrophy with <scp>COVID</scp>â€19 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database. Muscle and Nerve, 2022, 66, 766-770.	1.0	7
379	Comment on: "A Disproportionality Analysis of Drugâ€"Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)". Drug Safety, 0, , .	1.4	1
380	Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors. Medicina (Lithuania), 2022, 58, 1495.	0.8	0
381	Hepatobiliary calculi associated with ceftriaxone treatment: An analysis of FAERS data from 2004 to 2021. Journal of Infection and Chemotherapy, 2023, 29, 136-142.	0.8	1
382	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS ONE, 2022, 17, e0272022.	1.1	4
383	Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. Frontiers in Pharmacology, 0, 13, .	1.6	3
384	Do antibodyâ€"drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study. Frontiers in Pharmacology, 0, 13, .	1.6	4
385	Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBaseÂ®). BioDrugs, 2023, 37, 73-87.	2.2	5
386	Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS. Therapeutic Advances in Drug Safety, 2022, 13, 204209862211432.	1.0	3
387	Adverse events in pregnant women with the tetravalent influenza vaccine obtained from cell cultures. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2022, , .	0.2	0
388	Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19. Pharmaceuticals, 2022, 15, 1472.	1.7	1
389	Immunogenomic correlates of immune-related adverse events for antiâ€"programmed cell death 1 therapy. Frontiers in Immunology, 0, 13, .	2.2	4
390	Characterization of Immune Checkpoint Inhibitorâ€"Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System. Journal of Clinical Pharmacology, 0, , .	1.0	2
391	Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database. Frontiers in Pharmacology, 0, 13, .	1.6	3

#	Article	IF	Citations
392	Association between use of febuxostat and muscle injury: A disproportionality analysis and metaâ€analysis of randomized controlled trials. British Journal of Clinical Pharmacology, 2023, 89, 956-966.	1.1	1
393	Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021. Journal of Thrombosis and Haemostasis, 2023, 21, 546-552.	1.9	10
394	Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study. Bone, 2023, 168, 116647.	1.4	6
395	Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study. Cancers, 2023, 15, 240.	1.7	5
396	An open-source platform integrating emerging data sources to support multi-modal active pharmacovigilance. Frontiers in Drug Safety and Regulation, 0, 2, .	0.5	2
397	Optimize and Strengthen Machine Learning Models Based on in Vitro Assays with Mechanistic Knowledge and Real-World Data. Computational Methods in Engineering & the Sciences, 2023, , 183-198.	0.3	0
398	Increased odds of mortality from non-malignant respiratory disease and lung cancer are highest among US coal miners born after 1939. Occupational and Environmental Medicine, 2023, 80, 121-128.	1.3	3
399	Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Drug, Healthcare and Patient Safety, 0, Volume 15, 25-38.	1.0	6
400	Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS). Annals of Pharmacotherapy, 2023, 57, 1137-1146.	0.9	4
401	Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System. Drug Safety, 2023, 46, 283-295.	1.4	5
402	Cardiac toxicity associated with pharmacokinetic drugâ€"drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report. British Journal of Clinical Pharmacology, 2023, 89, 1486-1490.	1.1	2
403	Real-world evidence of autoimmune hepatitis following COVID-19 vaccination: A population-based pharmacovigilance analysis. Frontiers in Pharmacology, 0, 14, .	1.6	1
404	Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database. Antibiotics, 2023, 12, 240.	1.5	1
405	Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase. Drugs - Real World Outcomes, 2023, 10, 263-270.	0.7	3
406	Potential and Pitfalls of Pharmacovigilance Databases in Oncology. JACC: CardioOncology, 2023, 5, 99-101.	1.7	0
407	Proton Pump Inhibitors and Rhabdomyolysis: Analysis of Two Different Cross-Sectional Databases. Annals of Pharmacotherapy, 2023, 57, 1255-1263.	0.9	1
408	Depression and suicidality with VMAT2 inhibitors in tardive dyskinesia A signal detection from the FDA Adverse Events Reporting System. , 2023, 2, .		0
409	An evaluation of adverse drug reactions and outcomes attributed to kratom in the <scp>US</scp> Food and Drug Administration Adverse Event Reporting System from January 2004 through September 2021. Clinical and Translational Science, 2023, 16, 1002-1011.	1.5	2

#	Article	IF	Citations
410	Comment on: â€œAdverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysisâ€• International Journal of Cancer, 0, , .	2.3	0
411	Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database. Frontiers in Pharmacology, 0, 14, .	1.6	6
412	Dysautonomia associated with immune checkpoint inhibitors. Journal of Neurology, 2023, 270, 3413-3423.	1.8	4
413	Pharmacoepidemiology. , 2022, , 1-55.		0
414	Updated insights on <scp>dementiaâ€•related</scp> risk of sacubitril/valsartan: A <scp>realâ€•world</scp> pharmacovigilance analysis. CNS Neuroscience and Therapeutics, 2023, 29, 2548-2554.	1.9	3
415	Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions. BMC Medical Research Methodology, 2023, 23, .	1.4	4
416	Bayesian generalized linear low rank regression models for the detection of vaccineâ€•adverse event associations. Statistics in Medicine, 0, , .	0.8	0
417	Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis. Frontiers in Oncology, 0, 13, .	1.3	2
418	Appendicitis Associated With Clozapine. Journal of Clinical Psychopharmacology, 0, Publish Ahead of Print, .	0.7	0
421	Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System. Journal of Clinical Pharmacology, 2023, 63, 903-908.	1.0	3
422	PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS). Expert Opinion on Drug Safety, 2024, 23, 257-267.	1.0	0
423	Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine, 2023, 59, 101967.	3.2	11
459	Stacking Ensemble of Disproportionality Indicators for Adverse Vaccine Reactions Detectionâ€”An Empirical Study on Predicting Adverse Reactions of COVID-19 Vaccines. , 2023, , .		0